DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Urso (Ursodiol) - Summary

 
 



URSO SUMMARY

URSO 250® (ursodiol, 250 mg) and URSO Forte™ (ursodiol, 500 mg) are available as film-coated tablets for oral administration. Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring bile acid found in small quantities in normal human bile and in larger quantities in the biles of certain species of bears. It is a bitter-tasting white powder consisting of crystalline particles freely soluble in ethanol and glacial acetic acid, slightly soluble in chloroform, sparingly soluble in ether, and practically insoluble in water.

URSO 250® and URSO Forte™ (ursodiol) tablets are indicated for the treatment of patients with primary biliary cirrhosis.


See all Urso indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Urso (Ursodiol)

Two-pronged attack on chemotherapy-resistant leukemia cells
Source: Cancer / Oncology News From Medical News Today [2016.05.19]
All stems from malignant transformed precursor lymphocytes, the blood's defense cells. Nowadays, four out of five young leukemia patients can be treated successfully with aggressive chemotherapy.

A better understanding of bananas could help prevent blindness
Source: Eye Health / Blindness News From Medical News Today [2016.04.21]
Carotenoids, which are found at various levels in different banana cultivars, are important vitamin precursors for eye health.

Lamprey-derived antibody specifically recognizes human plasma cells
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2016.03.18]
Antibody-secreting plasma cells arise from B cell precursors and are essential for adaptive immune responses against invading pathogens.

Primary Biliary Cirrhosis (PBC)
Source: MedicineNet Thyroiditis Specialty [2015.11.23]
Title: Primary Biliary Cirrhosis (PBC)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/23/2015 12:00:00 AM

Primary Biliary Cirrhosis Treatment (PBC)
Source: MedicineNet budesonide nasal inhaler-spray Specialty [2015.09.25]
Title: Primary Biliary Cirrhosis Treatment (PBC)
Category: Diseases and Conditions
Created: 8/21/2001 12:00:00 AM
Last Editorial Review: 9/25/2015 12:00:00 AM

more news >>

Published Studies Related to Urso (Ursodiol)

[Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial]. [Article in Korean] [2014]
ursodeoxycholic acid (UDCA) in patients with abnormal ALT... CONCLUSIONS: DDB was not inferior to UDCA for normalizing ALT level. Furthermore

Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. [2013]
No direct comparison of tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) has yet been carried out in the treatment of liver cirrhosis in China... However, both drugs exert no effect on the serum markers for liver fibrosis during 6-month treatment.

Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross-over trial. [2012]
To evaluate the efficacy and safety of ursodeoxycholic acid (UDCA) with oral solubilized formula in amyotrophic lateral sclerosis (ALS) patients, patients with probable or definite ALS were randomized to receive oral solubilized UDCA (3.5 g/140 mL/day) or placebo for 3 months after a run-in period of 1 month and switched to receive the other treatment for 3 months after a wash-out period of 1 month...

Colchicine or methotrexate, with ursodiol, are effective after 20 years in a subset of patients with primary biliary cirrhosis. [2011.09]
BACKGROUND & AIMS: The combination of ursodeoxycholic acid (UDCA), colchicine, and methotrexate (MTX) is effective therapy for a subset of patients with primary biliary cirrhosis (PBC) who do not respond to UDCA. However, the durability of the response is unclear. We investigated whether the response to combination therapy was durable... CONCLUSIONS: Treatment with the combination of UDCA and MTX or UDCA and colchicine led to sustained clinical remission in a subset of patients with PBC. The response to the combination of UDCA and MTX appeared to be more durable than to UDCA and colchicine. Copyright (c) 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. [2011.09]
OBJECTIVES: Some studies have suggested that ursodeoxycholic acid (UDCA) may have a chemopreventive effect on the development of colorectal neoplasia in patients with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC). We examined the effects of high-dose (28-30 mg/kg/day) UDCA on the development of colorectal neoplasia in patients with UC and PSC... CONCLUSIONS: Long-term use of high-dose UDCA is associated with an increased risk of colorectal neoplasia in patients with UC and PSC.

more studies >>


Page last updated: 2016-05-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015